An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer

Trial Profile

An Open-label, Randomized Phase I Study Investigating Safety, Tolerability, Pharmacokinetics, and Efficacy of Pembrolizumab (MK-3475) in Chinese Subjects With Non-Small-Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms KEYNOTE-032
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 Apr 2017 Status changed from recruiting to active, no longer recruiting.
    • 25 Jan 2017 Planned End Date changed from 1 Nov 2017 to 1 Apr 2019.
    • 25 Jan 2017 Planned primary completion date changed from 1 Nov 2017 to 1 Apr 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top